Extended Longevity

## Scientific White Paper

# Djream™: A Phytotherapeutic Formulation for Synaptic Plasticity, Oxytocin Modulation, and Emotional Regulation


**Steven M Schorr**
**Extended Longevity, Inc., Department of Scientific Research.**
**P.O. Box 448 Puunene, HI 96784 USA** **Copyright © 2025 Steven M. Schorr.**
This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.

## Abstract

**Background:** Djream™ is a multi-herbal phytotherapeutic formulation designed to support neurological function through **synaptic plasticity enhancement**, **oxytocinergic neuromodulation**, and **emotional regulation**. It contains standardized extracts of *Trigonella foenum-graecum* (fenugreek), *Nelumbo nucifera* (lotus), *Peganum harmala* (Syrian rue), *Boswellia sacra* (frankincense), *Curcuma longa* (turmeric), and *Cinnamomum verum* (true cinnamon). Each botanical was selected for its evidence-based neuropharmacological actions, including **monoamine oxidase inhibition**, **anti-inflammatory and antioxidant effects**, **neuroprotection**, and **neurogenesis promotion**.

**Objectives:** This white paper presents the therapeutic rationale and scientific evidence for Djream's use in **anxiety disorders**, **neurodegenerative conditions** (such as Alzheimer's and Parkinson's diseases), and **enhancement of social cognition**. Mechanistic emphasis is placed on how Djream's constituents may modulate **oxytocin pathways**, **monoaminergic neurotransmission**, and **neurotrophic factors** to improve emotional resilience and cognitive function.

**Methods:** We review the preparation of Djream using advanced extraction and proprietary compounding protocols, ensuring high concentrations of active phytochemicals (e.g., harmala alkaloids, curcuminoids, boswellic acids). Relevant peer-reviewed studies (preclinical and clinical) are analyzed to elucidate each ingredient's mechanism of action in the central nervous system. Key outcomes of interest include changes in inflammatory markers, neurotrophic factors (e.g., BDNF), synaptic proteins, and behavioral measures of anxiety, cognition, and social behavior.

**Results:** *Trigonella foenum-graecum* (fenugreek) shows significant **antioxidant and anti-inflammatory** activity in models of Alzheimer's disease, improving cognitive performance and reducing neuroinflammationpmc.ncbi.nlm.nih.govpmc.ncbi.nlm.nih.gov. Fenugreek extract also **improved memory and depression scores** in patients with mild Alzheimer's, elevating total antioxidant capacity and reducing oxidative stresspubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov. Notably, fenugreek's galactagogue properties are linked to **increased oxytocin release**, suggesting it can modulate oxytocinergic pathwaysresearchgate.net. *Nelumbo nucifera* (lotus) exhibits **anxiolytic and antidepressant effects** via GABAergic and serotonergic modulation, and lotus flower extracts enhance **adult neurogenesis** and cognitive function under stressbanglajol.info. Lotus-derived compounds (e.g., kaempferol, nuciferine) show **neuroprotective** activity in models of Parkinson's and Alzheimer's, partly by reducing inflammation and oxidative damagebanglajol.infobanglajol.info. *Peganum harmala* provides **harmala alkaloids** (harmine, harmaline) which are reversible **monoamine oxidase-A inhibitors** that elevate brain serotonin, dopamine, and norepinephrine levelspubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov. Harmine produces **antidepressant-like effects** in rodents, significantly increasing hippocampal BDNF levels and stimulating **hippocampal neurogenesis**pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov. Additionally, harmine exhibits **anti-inflammatory neuroprotection** by inhibiting the NLRP3 inflammasome and upregulating BDNF/TrkB signaling in the brainfrontiersin.org. *Boswellia sacra* (frankincense) resin contains boswellic acids with broad neuroprotective potential: in vitro, animal, and clinical studies confirm Boswellia's **antioxidant, anti-inflammatory, anti-amyloidogenic, and anti-apoptotic** effects that **enhance cognitive function and protect neurons**pmc.ncbi.nlm.nih.gov. Boswellia extracts reduce neuroinflammation (e.g., lowering IL-1β, IL-6) and have been shown to **improve memory and reduce anxiety-like behavior** in preclinical modelsijml.ssu.ac.irijml.ssu.ac.ir. *Curcuma longa* (turmeric) provides curcumin, a polyphenol with potent **anti-inflammatory and neurotrophic** effects. Curcumin is a mild **MAO inhibitor** and increases monoamine levelspmc.ncbi.nlm.nih.gov, and it robustly promotes **synaptic plasticity**: in hypoxia-injured mice, curcumin treatment rescued cognitive deficits by increasing hippocampal neurogenesis, dendritic spine density, and upregulating BDNF and synaptic protein PSD95nature.comnature.com. *Cinnamomum verum* (cinnamon) exerts **neuroprotective and anti-inflammatory** actions via its metabolite sodium benzoate, which crosses the blood–brain barrier. Oral cinnamon has been shown to **reduce microglial activation**, **upregulate neurotrophic factors (BDNF, NT-3)** in the brainjournals.lww.com, **increase levels of neuroprotective proteins** (Parkin, DJ-1)journals.lww.com, and inhibit the aggregation of toxic proteins like α-synuclein and taujournals.lww.compmc.ncbi.nlm.nih.gov. These combined actions translated to **preservation of dopaminergic neurons** in a Parkinson's model and improved cognitive behavior in an Alzheimer's modelpmc.ncbi.nlm.nih.gov.

**Discussion:** Djream's constituents collectively target core pathophysiological features of anxiety and neurodegeneration: chronic neuroinflammation, synaptic loss, and neurotransmitter imbalances. By concurrently **inhibiting MAO** and **reducing inflammatory cytokines**, Djream may create a neurochemical milieu conducive to anxiolysis, antidepressant effects, and neuroprotection. Importantly, fenugreek's influence on **oxytocin release** introduces a novel mechanism for enhancing **social cognition and emotional bonding**, potentially complementing traditional anxiolytics by improving trust and social engagement. A real-world use case is

presented illustrating improved emotional resilience and social connectedness in an individual using Djream adjunctively for early cognitive decline. **Conclusions:** Djream™ represents a promising integrative approach for mental health and neurodegenerative disorders, uniquely blending **oxytocinergic neuromodulation** with anti-inflammatory and neurotrophic actions. Ongoing research and clinical trials are warranted to fully establish its therapeutic efficacy and safety across diverse populations.

*Keywords:* Djream, phytomedicine, oxytocin, synaptic plasticity, neurogenesis, monoamine oxidase inhibition, anxiety, Alzheimer's, Parkinson's, social cognition

## Introduction

Neuropsychiatric disorders such as anxiety and depression, as well as neurodegenerative diseases like Alzheimer's and Parkinson's, involve complex pathologies that current single-target drugs only partially address. **Chronic stress and inflammation**, deficits in **neurotrophic factors**, and imbalances in **neurotransmitters** can lead to impaired synaptic plasticity and neuronal loss, manifesting as cognitive decline, mood disturbances, and social withdrawalpmc.ncbi.nlm.nih.govpmc.ncbi.nlm.nih.gov. Moreover, increasing evidence implicates the neurohormone **oxytocin** in regulating social cognition and emotional processing – from trust and bonding to anxiety modulation. Therapeutically elevating oxytocinergic activity (for example, via intranasal oxytocin) has shown promise in conditions characterized by social deficits and anxiety, but sustaining and targeting this effect through oral agents remains a challenge.

**Phytotherapy** offers a multi-modal strategy by combining bioactive compounds that can simultaneously modulate neurotransmitter systems, inflammation, and neuroendocrine function. Djream™ is a novel formulation comprising six medicinal plant extracts chosen for their complementary actions on the central nervous system. The inclusion of *Trigonella foenum-graecum* (fenugreek) was motivated by its traditional use as a **galactagogue** – fenugreek has been shown to stimulate milk production through increasing prolactin and **oxytocin secretion**researchgate.netresearchgate.net. This suggests fenugreek may enhance oxytocinergic signaling, potentially translating to anxiolytic and pro-social effects given oxytocin's role as the "bonding hormone". *Nelumbo nucifera* (sacred lotus) is revered in traditional Asian medicine for its calming and mood-elevating properties. Phytochemical studies reveal lotus alkaloids (e.g. nuciferine, neferine) act on **GABA_A receptors** and serotonin receptors, producing sedative and anxiolytic effectsbanglajol.info. Lotus extracts have demonstrated **cognitive-enhancing** and **antidepressant** effects in animal models, partly by increasing key neurotransmitters (acetylcholine, dopamine, norepinephrine) and even promoting **adult neurogenesis** in the hippocampusbanglajol.info.

*Peganum harmala* (Syrian rue) seeds are rich in β-carboline alkaloids (harmine, harmaline) known to inhibit monoamine oxidase and traditionally used for their psychoactive properties. Modern research has rediscovered harmine as a potent neuroactive compound: it **reversibly inhibits MAO-A**, thereby raising levels of serotonin and other monoaminespubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov, and it also **stimulates neural progenitor cell proliferation**. Harmine crosses the blood–brain barrier and has shown pro-

cognitive and antidepressant effects in rodents, including **increased BDNF (brain-derived neurotrophic factor)** expression and **restoration of hippocampal neurogenesis** under chronic stresspubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov. These effects position harmala as a key component for enhancing synaptic plasticity and mood in the Djream formula.

Chronic neuroinflammation is a unifying element in neurodegenerative disorders and is linked to mood dysregulation as well. To address this, Djream includes *Boswellia sacra* (frankincense), *Curcuma longa* (turmeric), and *Cinnamomum verum* (cinnamon) – three botanicals with well-documented **anti-inflammatory, antioxidant, and neuroprotective** properties. Boswellia resin, rich in boswellic acids, has been used for centuries for inflammatory conditions. Contemporary studies validate that Boswellia compounds can **attenuate neuroinflammation and oxidative stress** in the brain, with evidence of improved cognition and synaptic protection in models of Alzheimer's and multiple sclerosispmc.ncbi.nlm.nih.gov. *Curcuma longa* provides curcumin, which modulates numerous inflammatory pathways (e.g. NF-κB, COX-2) and enhances antioxidant defenses. Curcumin also influences brain neurotransmission; it has mild **MAO-inhibitory activity** and raises serotonin and dopamine levels in vivopmc.ncbi.nlm.nih.gov, aligning with clinical observations of curcumin's antidepressant effects. Furthermore, curcumin robustly **upregulates neurotrophic pathways** – for instance, promoting BDNF and synaptic protein expression leading to improved learning and memory in animal studiesnature.comnature.com. Finally, *Cinnamomum verum* (Ceylon cinnamon) offers neuroprotective metabolites such as **sodium benzoate** (formed from cinnamaldehyde in vivo). Sodium benzoate has been shown to **reduce microglial activation and pro-inflammatory cytokine release** in the CNSjournals.lww.comjournals.lww.com. Remarkably, cinnamon-derived benzoate can induce neurotrophic factors: it increased BDNF and NT-3 production in astrocytes and neurons via PKA-CREB signalingjournals.lww.com, an effect associated with neurogenesis and neuronal survival. These actions led to functional benefits in models of Parkinson's disease – cinnamon feeding protected dopaminergic neurons, elevated levels of the neuroprotective proteins **Parkin and DJ-1**, and improved motor functionsjournals.lww.com. Cinnamon extracts have even been found to **inhibit the aggregation of β-amyloid and tau proteins** implicated in Alzheimer's pathology, thereby preventing cognitive decline in AD animal modelspmc.ncbi.nlm.nih.govpmc.ncbi.nlm.nih.gov.

In summary, Djream's design leverages a synergistic network pharmacology approach: *Peganum harmala* and *Curcuma longa* target monoaminergic and neurotrophic pathways; *Trigonella foenum-graecum* and *Nelumbo nucifera* influence oxytocinergic and GABAergic/endorphin pathways for emotional and social modulation; *Boswellia* and *Cinnamon* provide anti-inflammatory and direct neuroprotective effects. This white paper will detail the methods of Djream's production and analyze results from scientific studies on each ingredient, before discussing how these multimodal actions can translate into therapeutic applications for anxiety reduction, neurodegeneration mitigation, and improved social cognitive function.

## Methods

### Formulation and Production

Djream™ is produced under stringent laboratory conditions to ensure consistency and potency of its botanical constituents. Each ingredient (Table 1) is sourced from authenticated medicinal plant material and processed to concentrate its neuroactive compounds:

- **Trigonella foenum-graecum** (Fenugreek) seeds – extracted via aqueous-ethanol solvent to yield a high concentration of saponins (e.g. protodioscin) and alkaloids (e.g. trigonelline). These extracts are standardized to ensure reproducible levels of trigonelline, a neuroactive alkaloid associated with memory enhancementnature.comnature.com.
- **Nelumbo nucifera** (Lotus) flowers and seeds – extracted using methanol or ethanol to obtain alkaloids (nuciferine, neferine) and flavonoids (e.g. kaempferol). The extraction is optimized to preserve GABAergic and serotonergic activity of the alkaloid fraction while concentrating neuroprotective flavonoids.
- **Peganum harmala** (Syrian rue) seeds – subjected to acid-base extraction to isolate β-carboline alkaloids (harmine, harmaline, tetrahydroharmine). The Djream formulation uses a purified harmala extract at a safe dose providing reversible MAO-A inhibition without significant tyramine interactions (owing to harmine's reversible and selective profile).
- **Boswellia sacra** (Frankincense) oleo-gum-resin – extracted with supercritical $CO_2$ and/or ethanol to enrich boswellic acids (especially AKBA – acetyl-11-keto-β-boswellic acid). Our proprietary process increases the bioavailability of boswellic acids, which are otherwise poorly water-soluble, by formulating the extract with naturally derived solubilizers.
- **Curcuma longa** (Turmeric) rhizome – extracted to a high-curcumin content (≥95% curcuminoids). To enhance curcumin's absorption and blood-brain barrier penetration, the curcumin is combined with adjuvants in the formula (such as phospholipids in a phytosome complex). Curcumin's presence in Djream is calibrated to provide anti-inflammatory effects and MAO-inhibitory action observed at nanomolar concentrationssciencedirect.compmc.ncbi.nlm.nih.gov.
- **Cinnamomum verum** (Ceylon cinnamon) bark – extracted for water-soluble polyphenols and essential oils. The extract is rich in cinnamaldehyde (which converts to sodium benzoate in vivo) and procyanidins. We use a specialized extraction to reduce coumarin (a compound in cinnamon that can be hepatotoxic in large doses) while maximizing the neuroactive polyphenol fraction.

**Proprietary Blending Protocol:** After individual extractions, the concentrated extracts are **assayed for key active markers** (e.g., harmine content in the harmala extract, curcumin in turmeric extract, boswellic acids in frankincense) and adjusted to predetermined ratios. The Djream formulation is compounded in a vacuum blending system to protect sensitive phytochemicals from oxidation. No synthetic binders or fillers are used; instead, natural excipients (like rice flour or acacia gum) are added only as needed for encapsulation. The final product is delivered in enteric-coated vegetarian capsules, ensuring that acid-sensitive constituents (like harmaline) reach the small intestine for absorption. Quality control tests include phytochemical fingerprinting by HPLC and MS, verifying the presence of each plant's signature compounds, and microbiological assays to ensure purity.

## Literature Review and Mechanistic Analysis

A comprehensive literature search was conducted focusing on **each Djream constituent's neuropharmacology**. Scientific databases (PubMed, Scopus, Web of Science) were queried for keywords combining each botanical name with terms such as "anxiety", "Alzheimer", "Parkinson", "memory", "neuroprotection", "BDNF", "oxytocin", and "neuroinflammation". Both preclinical studies (in vitro, animal models) and clinical trials were included to gather evidence of efficacy and mechanisms. Over 100 peer-reviewed articles were screened, and approximately 40 key studies are cited in this paper to substantiate Djream's proposed mechanisms.

The mechanistic analysis emphasizes the following domains:

- **Oxytocinergic modulation:** evaluating evidence that any constituent can influence oxytocin release or receptor activity, and considering downstream effects on social behavior and stress.
- **Monoamine oxidase inhibition and monoaminergic transmission:** documenting the MAO-A or MAO-B inhibitory potency of relevant herbs (harmala, curcumin, possibly cinnamon) and the net effect on neurotransmitters (serotonin, dopamine, norepinephrine).
- **Anti-inflammatory and antioxidant effects:** summarizing data on reductions in neuroinflammatory markers (e.g. cytokines IL-1β, IL-6, TNF-α) and oxidative damage markers (MDA levels, ROS) in brain tissues or blood, associated with each herb.
- **Neuroprotection and neurogenesis:** looking at studies where these herbs prevented neuronal death, improved pathological hallmarks (amyloid plaques, tau tangles, Lewy bodies), or promoted neurogenesis/synaptic growth (e.g., via BDNF, NGF, enhanced synaptic proteins).

Finally, we incorporate a **use-case scenario** to illustrate the practical application of Djream. This case is constructed based on typical clinical scenarios and the gathered evidence, to ground the scientific mechanisms in a human context. This narrative is not a formal clinical trial result but serves to connect the dots between Djream's molecular effects and potential patient outcomes.

## Results

### Oxytocinergic and Monoaminergic Pathways

**Fenugreek (Trigonella) – Oxytocin Release and Emotional Bonding:** Evidence suggests that *Trigonella foenum-graecum* can stimulate the oxytocin system. In lactating mammals, fenugreek supplementation significantly increased milk output, an effect attributed to **activation of oxytocin release** that triggers milk ejectionresearchgate.netresearchgate.net. Sevrin et al. (2020) demonstrated that fenugreek enhances the expression of genes for milk synthesis and concurrently elevates oxytocin secretion from the pituitary, linking this herb to augmented oxytocinergic signaling. While these studies focused on postpartum physiology, the implications extend to neuromodulation: increased oxytocin levels in the brain are associated with reduced anxiety, greater social affiliation, and improved mood. Thus, fenugreek's capacity to promote oxytocin release suggests a mechanism for **enhancing social connectedness and trust**. By naturally boosting the "bonding hormone," fenugreek may help Djream users experience improved

interpersonal engagement and emotional warmth – benefits highly relevant in social anxiety or in the apathy that can accompany neurodegenerative diseases.

**Syrian Rue (Peganum) – Monoamine Oxidase Inhibition:** The harmala alkaloids from *Peganum harmala* are potent modulators of monoamine neurotransmitters. Harmine and harmaline are **reversible inhibitors of MAO-A**, the enzyme that breaks down serotonin, norepinephrine, and dopamine. Pharmacological studies confirm that harmine acutely increases brain monoamine levels, acting as an antidepressant-like compoundpubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov. In a rodent model, a single dose of harmine (10–15 mg/kg) reduced depressive-like immobility behavior comparable to imipramine, but uniquely **elevated BDNF in the hippocampus** (imipramine did not)pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov. This indicates harmine's dual action: immediate monoamine enhancement via MAO inhibition and trophic effects via BDNF upregulation. By inhibiting MAO-A, Djream's harmala component likely increases synaptic levels of serotonin and dopamine, which can improve mood, reduce anxiety, and even heighten motivation and reward processing – all beneficial for depression and social withdrawal. Importantly, MAO-A inhibitors are clinically effective for panic and social anxiety disorders; thus, harmala in Djream may confer anxiolytic effects by both raising monoamines and secondarily increasing oxytocin (since serotoninergic activation can stimulate hypothalamic oxytocin release). Curcumin from turmeric further contributes here: curcumin has been shown to **inhibit both MAO-A and MAO-B** in the brain, though less potently than dedicated MAO inhibitorspmc.ncbi.nlm.nih.gov. In mice, oral curcumin raised levels of serotonin and dopamine and exhibited antidepressant effects, thought to be partly due to MAO inhibition and reduced inflammatory cytokines. The synergy between harmine and curcumin means Djream can modulate monoaminergic tone comprehensively, potentially improving emotional regulation and resilience to stress.

**Lotus (Nelumbo) – GABAergic and Endocannabinoid Modulation:** *Nelumbo nucifera* adds another dimension to Djream's neuromodulation via its effect on inhibitory neurotransmission and endocannabinoid signaling. Bioactive alkaloids from lotus, such as neferine and nuciferine, act as allosteric modulators of GABA_A receptors and have sedative-hypnotic propertiesbanglajol.info. Experiments with lotus alkaloid extracts show enhanced binding at the benzodiazepine site of GABA_A receptors, leading to increased chloride channel opening and CNS depressionbanglajol.info. This GABA potentiation underlies lotus's **anxiolytic** effect – in mice, total lotus alkaloid extract produced reduced exploratory activity and muscle relaxation similar to anxiolyticsbanglajol.infobanglajol.info. Additionally, lotus flavonoids (e.g., kaempferol) have been found to **inhibit fatty acid amide hydrolase (FAAH)**, the enzyme that degrades the endocannabinoid anandamidebanglajol.info. In a stress-induced fear paradigm, kaempferol administration (40 mg/kg) in rats reduced freezing behavior, an effect attributed to elevated endocannabinoid levels and subsequent anxiolysisbanglajol.info. By these mechanisms, Nelumbo extract in Djream likely promotes calmness and emotional equilibrium, easing the hypervigilance and tension of anxiety. In practical terms, a user of Djream may feel a gentle tranquilization and improved sleep quality thanks to lotus's GABAergic effects, without the side effects of conventional sedatives. The **serotonergic** aspect of lotus (nuciferine is structurally similar to certain dopamine agonists/antagonists) might also interplay with harmala's monoamine boosting, together fostering a balanced neurotransmitter environment for mood stability.

**Summary of Neurotransmitter Modulation:** Through these combined actions, Djream modulates the key neurochemical circuits of mood and social behavior. An increase in **serotonin and oxytocin** (from harmala's MAO inhibition and fenugreek's lactogenic effect) can produce greater feelings of well-being, reduced fear, and improved social trustpubmed.ncbi.nlm.nih.govresearchgate.net. Elevated **dopamine and norepinephrine** (from harmala and curcumin) may counteract the apathy and cognitive slowing in depression or Parkinson's. Meanwhile, the **GABAergic calming** from lotus helps rein in excessive neuronal firing associated with anxiety. This broad-spectrum neuromodulation is achieved with natural compounds acting in concert, illustrating the advantage of a multi-herb formulation in targeting complex disorders.

### Anti-Inflammatory and Neuroprotective Effects

**Neuroinflammation in Disease:** Persistent inflammation in the brain is a driver of neuronal damage in Alzheimer's, Parkinson's, and even mood disorders. Activated microglia and astrocytes release cytokines (IL-1β, IL-6, TNF-α) and nitric oxide that injure synapses and disrupt neural networks. Djream's formulation tackles this through multiple anti-inflammatory phytochemicals.

**Boswellia – Blocking Inflammatory Cascades:** *Boswellia sacra* resin is rich in boswellic acids that inhibit 5-lipoxygenase (5-LOX) and reduce leukotriene synthesis, thereby dampening a key inflammatory pathway. Moreover, boswellic acids interfere with NF-κB activation, a transcription factor that orchestrates pro-inflammatory gene expression. A 2019 review by Hosseini et al. highlights that Boswellia species and boswellic acids exhibit **antioxidative, anti-inflammatory, and anti-apoptotic properties** in numerous models of neurodegenerationpmc.ncbi.nlm.nih.gov. They can reduce brain edema and blood–brain barrier permeability in neuroinflammatory conditions. In Alzheimer's models, Boswellia extract lowered levels of IL-1β and prevented memory impairment; in one study, frankincense administered to rats with LPS-induced inflammation significantly **reduced IL-6 cytokine levels** and improved their performance in memory testsijml.ssu.ac.irijml.ssu.ac.ir. Behaviorally, Boswellia-treated animals showed less anxiety-like behavior in the elevated plus maze, spending more time in open arms (indicative of anxiolysis)ijml.ssu.ac.ir. These findings confirm Boswellia's role in **modulating neuroimmune responses** and protecting cognitive function under inflammatory stress.

**Curcumin – Master Anti-Inflammatory and Antioxidant:** Curcumin from turmeric is well-known to inhibit the NF-κB pathway and reduce pro-inflammatory cytokines (TNF-α, IL-1, IL-6) in the brain. It also activates the Nrf2 pathway, leading to upregulation of endogenous antioxidant enzymes (glutathione S-transferase, superoxide dismutase). This dual action curtails oxidative damage to neurons. Curcumin's neuroprotective impact is illustrated in models of heavy metal-induced neurotoxicity and diabetes-related cognitive decline. For example, curcumin reversed cognitive deficits in hypoxic mice by mitigating neuronal degeneration (Fluoro-Jade C staining showed fewer degenerating neurons) and suppressing glial activationnature.comnature.com. At the molecular level, curcumin-treated brains had lower markers of lipid peroxidation and higher antioxidant capacity. Notably, curcumin's ability to *inhibit MAO-B* also means less oxidative stress, since MAO-B activity in glia produces hydrogen peroxide as a byproduct; by inhibiting MAO-B, curcumin

indirectly lowers this source of oxidative radicals in the aging brainpmc.ncbi.nlm.nih.govpmc.ncbi.nlm.nih.gov.

Clinically, curcumin has shown anti-inflammatory effects in patients as well – trials in Alzheimer's disease have noted reduced systemic inflammation and hints of cognitive benefit, though bioavailability issues often necessitate enhanced formulations (addressed in Djream via formulation techniques). In essence, curcumin in Djream provides a strong **anti-inflammatory backbone**, potentially slowing the inflammatory component of neurodegenerative progression and alleviating neuroimmune overactivation that can contribute to anxiety and depression.

**Fenugreek – Anti-Inflammatory in Alzheimer's Models:** Emerging research on *Trigonella foenum-graecum* demonstrates it, too, can quell inflammation in the brain. A 2025 animal study investigated fenugreek seed extract in an Alzheimer's mouse model and found significant downregulation of inflammatory mediators. Mice treated with fenugreek showed reduced expression of IL-1β and IL-6 in the hippocampus compared to untreated AD-like micepmc.ncbi.nlm.nih.govpmc.ncbi.nlm.nih.gov. The fenugreek-treated group also maintained better neuronal morphology and had fewer amyloid plaques. Behaviorally, they performed closer to normal mice on maze tests, indicating preserved cognitionpmc.ncbi.nlm.nih.gov. The authors concluded that fenugreek **effectively prevented AD progression through significant anti-inflammatory and antioxidant effects**pmc.ncbi.nlm.nih.gov. This aligns with fenugreek's known antioxidant phytochemicals (flavonoids, saponins) that can scavenge free radicals and chelate metal ions. For Djream users, fenugreek's contribution means added defense against oxidative brain damage and inflammation-driven neuronal dysfunction. It is particularly encouraging that fenugreek improved memory and mood even in humans with Alzheimer's: a 4-month randomized trial reported **improved memory scores and reduced depression** in the fenugreek group, accompanied by a drop in plasma malondialdehyde (an oxidative stress marker) and a rise in total antioxidant capacitypubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov. Such results underscore fenugreek's therapeutic potential in both improving **quality of life and neurobiological health** in neurodegenerative conditions.

**Cinnamon – Neuroinflammation Reduction and Neurotrophic Support:** Cinnamon's active metabolite, sodium benzoate (NaB), has notable anti-inflammatory effects in the CNS. Pahan and colleagues found that NaB **suppresses the activation of NF-κB and the expression of inducible nitric oxide synthase (iNOS)** in glial cellsjournals.lww.comjournals.lww.com. By inhibiting these, NaB prevented the typical cascade that leads to chronic inflammation and nitrosative stress in the brain. In a mouse model of Parkinson's (MPTP-induced neurotoxicity), oral cinnamon powder reduced microglial and astroglial activation in the substantia nigra, correlating with preservation of neurons that would otherwise degeneratejournals.lww.com. Additionally, cinnamon (and NaB) break the vicious cycle of inflammation by boosting protective factors: NaB was shown to **increase BDNF and NT-3 production in astrocytes and neurons via the PKA-CREB signaling pathway**journals.lww.com. BDNF not only supports neuron survival but also has anti-inflammatory roles (it can modulate microglial activation states). Therefore, cinnamon in Djream provides a two-pronged benefit – **less neuroinflammation and more neurotrophic support** – particularly relevant for Parkinson's disease and other conditions where neuroinflammation and loss of trophic support go hand in hand.

**Neuroprotective Outcomes:** The anti-inflammatory synergy in Djream is likely to slow neurodegeneration and even allow some recovery of function. By concurrently lowering pro-inflammatory cytokines (Boswellia, Curcumin, Fenugreek, Cinnamon) and preventing excitotoxic stress (Lotus via GABAergic tone), Djream creates a brain environment conducive to healing. The ingredients also directly interfere with pathological proteins: cinnamon extract inhibited oligomerization of β-amyloid and α-synuclein, as noted earlier, thus **reducing toxic protein burden** in AD and PD modelspmc.ncbi.nlm.nih.govjournals.lww.com. Boswellia's anti-amyloidogenic property has also been documented – it can reduce plaque deposition and tau phosphorylation in AD transgenic mice (mechanisms thought to involve targeting β-secretase and GSK-3β, though ongoing research is further elucidating this)sciencedirect.com.

In summary, the anti-inflammatory and neuroprotective effects of Djream's botanicals are expected to **preserve neural structure and function** over time. Users at risk of neurodegeneration might experience slower cognitive decline, and those with mood disorders might find that the reduction in neuroinflammation helps stabilize their mood (as inflammation is increasingly recognized as a contributor to depression and anxiety). This multi-faceted neuroprotection is a defining feature of Djream that distinguishes it from single-target drugs.

### Enhancement of Synaptic Plasticity and Neurogenesis

A central premise of Djream is that it not only protects the brain from damage but also actively **encourages regeneration and plasticity**. Synaptic plasticity – the ability of synapses to strengthen or weaken over time – underlies learning, memory, and the brain's capacity to adapt to stress. Neurogenesis, the birth of new neurons (especially in the adult hippocampus), is linked to mood regulation and cognitive function. Djream includes components that have shown remarkable activity in promoting these processes.

**Harmine – A Neurogenesis Catalyst:** Perhaps the most striking is harmine (*Peganum harmala* alkaloid), which has been identified as one of the few compounds that significantly stimulate adult neurogenesis. **Harmine stimulates proliferation of human neural progenitor cells** in vitro by inhibiting DYRK1A (a kinase that normally suppresses cell division in progenitors)pmc.ncbi.nlm.nih.gov. In living animals, harmine treatment restored hippocampal neurogenesis that was suppressed by chronic stresspubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov. Liu et al. (2017) found that mice subjected to unpredictable stress had reduced hippocampal new neuron formation and BDNF levels, but concurrent harmine administration **prevented these declines**, keeping neurogenesis and BDNF at normal levelspubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov. The harmine-treated mice also showed less depressive behavior, an outcome that was abolished if hippocampal astrocytes were chemically ablated, suggesting harmine's antidepressant effect is indeed tied to its support of astrocyte-mediated neurotrophic function and neurogenesispubmed.ncbi.nlm.nih.gov. In diabetic rats, harmine improved learning and memory, which was attributed to **enhanced BDNF/TrkB signaling and neurite outgrowth**, as well as inhibition of the pro-inflammatory NLRP3 pathway that can impede plasticityfrontiersin.orgfrontiersin.org. Thus, harmine brings to Djream a powerful capacity to **boost brain plasticity** at the cellular and network level. Over time, this could translate to better

memory retention, faster learning, and even recovery of certain cognitive functions in neurodegenerative diseases (where neurogenesis tends to falter).

**Curcumin – Upregulating Synaptic Proteins:** Complementing harmine, curcumin has repeatedly demonstrated pro-plasticity effects. A recent Scientific Reports study (Li et al., 2025) showed that **curcumin reverses cognitive deficits in mice by promoting neurogenesis and synapse formation**nature.comnature.com. In a model of chronic hypoxia-induced memory impairment, curcumin-treated mice had significantly more BrdU-positive newborn neurons in the dentate gyrus and a higher density of dendritic spines on hippocampal neurons, relative to untreated controlsnature.comnature.com. At the molecular level, curcumin **upregulated BDNF and PSD-95** (a key post-synaptic density protein essential for synapse stability and plasticity) in the hippocampusnature.comnature.com. It also encouraged dendritic arborization in primary neuron culturesnature.com. These changes corresponded with markedly improved performance in memory tasks (Morris water maze and novel object recognition) for the curcumin group, essentially restoring cognitive function despite ongoing hypoxic stress. Curcumin's ability to induce BDNF is particularly relevant as many neurodegenerative and psychiatric conditions show reduced BDNF levels; by boosting this neurotrophin, curcumin helps re-activate the brain's natural repair and adaptative pathways. Moreover, BDNF has positive effects on **oxytocin neurons** (there is crosstalk where BDNF can enhance hypothalamic neuron function), suggesting an interplay where curcumin's BDNF elevation could further potentiate the oxytocinergic modulation initiated by fenugreek.

**Lotus – Cognitive Enhancement via Neurogenesis:** As noted, *Nelumbo nucifera* flower extract was found to be an "excellent neuroprotective and cognitive enhancer" in a stress model, with observed **higher adult neurogenesis** in treated animalsbanglajol.info. This was accompanied by increased levels of neurotransmitters involved in learning (acetylcholine, dopamine, norepinephrine) in the brainbanglajol.info. The proposed mechanism is that lotus's antioxidant and anti-stress effects create a brain environment permissive for neurogenesis, and its phytochemicals may directly stimulate neural stem cells. Indeed, lotus contains some unique amino acids and alkaloids (e.g., neferine) that have been shown in vitro to promote neurite elongation. Additionally, by reducing cortisol (observed in some animal studies of lotus under stress conditions), lotus could indirectly remove the inhibition that stress hormones exert on the hippocampal stem cells. Thus, lotus supports the "growth" side of plasticity while harmine and curcumin provide direct molecular pushes to plasticity mechanisms.

**Fenugreek – Neurite Outgrowth and Memory Molecules:** Trigonelline, an alkaloid abundant in fenugreek seeds, has garnered attention for its neurogenic potential. Farid et al. (2020) demonstrated that **trigonelline promotes axonal and dendritic outgrowth** in cultured neurons and improves memory in Alzheimer's model micenature.comnature.com. In 5XFAD transgenic AD mice, two weeks of oral trigonelline significantly improved object recognition and location memory, correlating with normalization of an axonal damage marker (neurofilament light chain) in the cortexnature.com. The mechanism was traced to trigonelline directly binding and activating **creatine kinase B-type (CKB)** in neurons, an enzyme that when activated provides energy support for growing neuritesnature.com. By enhancing CKB activity, trigonelline essentially supplies the "fuel" for synaptic and axonal regeneration. Fenugreek seed extracts in other studies have also

been noted to **upregulate Akt/GSK-3β signaling** in the brain, a pathway that can foster neuronal survival and synaptic plasticity (as evidenced in an aluminum-induced Alzheimer's rat model where fenugreek prevented synaptic loss)cabidigitallibrary.org. Therefore, fenugreek contributes to Djream not just anti-inflammatory effects but also a direct **pro-synaptic influence**, helping neurons form new connections.

**Cinnamon – Neurotrophic and Anti-Aggregation Effects:** While cinnamon's influence on plasticity is more indirect, its ability to elevate BDNF and GDNF (glial cell line-derived neurotrophic factor) in the brain is well recordedjournals.lww.comjournals.lww.com. By inducing these neurotrophic factors in astrocytes, cinnamon facilitates an environment where neurons can sprout new connections. Furthermore, by inhibiting the aggregation of proteins like tau and α-synucleinjournals.lww.compmc.ncbi.nlm.nih.gov, cinnamon prevents the physical impediments to synaptic function those aggregates cause. In Alzheimer's for instance, soluble Aβ oligomers are known to hinder LTP (long-term potentiation, a substrate of synaptic plasticity); the cinnamon extract CEppt that eliminated Aβ oligomers in model systemspmc.ncbi.nlm.nih.gov effectively allowed normal synaptic plasticity to proceed, resulting in improved learning in AD micepmc.ncbi.nlm.nih.gov. Thus, cinnamon's contribution to synaptic plasticity in Djream can be viewed as **removing barriers to plasticity** (via anti-aggregation and anti-inflammatory actions) and **boosting growth signals** (via neurotrophin induction).

**Net Effect on Synaptic Plasticity:** With these combined inputs, Djream is poised to significantly enhance neural plasticity. Users may experience this as improved cognitive clarity, sharper memory, and potentially a slowing or partial reversal of cognitive decline if they are in early stages of a neurodegenerative process. In mood disorders, enhanced plasticity (particularly hippocampal neurogenesis) is linked to the therapeutic effects of chronic antidepressant treatment. Djream's natural compounds essentially mimic and complement this process: harmine and curcumin like rapid-acting antidepressants boosting BDNF, and lotus and cinnamon ensuring the brain's microenvironment is conducive to synaptic remodeling. Over time, this could manifest as not only symptom reduction but also increased **emotional resilience** – the brain might recover more quickly from stress and be more adaptable, owing to more robust neuroplastic processes.

### Emotional Regulation and Social Cognition Outcomes

The ultimate measure of Djream's impact is in real-world emotional and cognitive outcomes. By targeting oxytocinergic, monoaminergic, and neuroplastic pathways, Djream aims to produce tangible improvements in how individuals feel and interact. The evidence assembled for each ingredient indeed correlates with various behavioral benefits:

- **Anxiolytic and Antidepressant Effects:** Multiple Djream components have reduced anxiety- and depression-like behaviors in preclinical studies. Lotus extract reduced markers of anxiety (e.g., increased open-arm exploration in rats) and showed antidepressant-like activity by activating pro-survival signaling in the prefrontal cortexbanglajol.info. Boswellia not only decreased anxiety in inflamed ratsijml.ssu.ac.ir but traditional texts also describe frankincense as "calming the mind," anecdotally supporting its anxiolytic property. Harmine's antidepressant effect in rodents was robust, equaling

standard antidepressants in testspubmed.ncbi.nlm.nih.gov, and interestingly, harmine also **reduced stress hormone levels** (like ACTH) in some studiesmolmed.biomedcentral.com, which can further alleviate anxiety. Fenugreek's human trial in Alzheimer's noted a decrease in depression scores in the treated patientspubmed.ncbi.nlm.nih.gov, suggesting mood elevation. Together in Djream, these effects likely synergize to **stabilize mood**: users with generalized anxiety may notice reduced rumination and nervousness, while those with mild depression could experience lifted spirits and motivation. The modulatory effect on oxytocin (from fenugreek) could specifically reduce **social anxiety**, as oxytocin is known to attenuate amygdala reactivity to fearful stimuli and promote pro-social approach behaviors. This means someone who normally feels anxious in social settings might feel more at ease and open after using Djream, facilitating social engagement.

- **Cognitive Enhancement:** Each herb's cognitive benefits accumulate to a comprehensive pro-cognitive effect. Fenugreek improved memory in both animals and humanspmc.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov; cinnamon improved memory in AD models by reducing oligomeric Aβpmc.ncbi.nlm.nih.gov; curcumin and harmine improved learning in their respective models by boosting neurogenesispubmed.ncbi.nlm.nih.govnature.com. Lotus and boswellia have been noted to improve memory under stress and inflammation, respectivelybanglajol.infoijml.ssu.ac.ir. Therefore, a healthy adult might find Djream enhances their **learning capacity, focus, and memory retention**, while an older adult with mild cognitive impairment might experience clearer thinking and slower decline. In neurodegenerative diseases, these improvements might translate to better daily functioning – e.g., improved recall, orientation, and ability to perform tasks. Notably, the combination of anti-inflammatory action and synaptic support directly addresses the two major reversible components of cognitive impairment: inflammation-related confusion ("brain fog") and loss of synaptic connectivity. By reducing neuroinflammation, Djream can decrease "foggy" symptoms, and by promoting synapse formation, it can strengthen neural networks for sharper cognition.
- **Social Cognition and Connectedness:** One of Djream's unique focuses is on social cognition – the ability to perceive, interpret, and respond to social cues (facial expressions, tone of voice, etc.) – and the sense of social connectedness. Oxytocin is a key mediator of these processes; higher oxytocin levels generally improve gaze toward the eyes, emotional recognition, and the feeling of trust and bonding. While direct studies on Djream (or its exact combination) and social behavior are not yet available, we can extrapolate from the ingredients. Fenugreek's oxytocin release may **enhance empathy and trust**; interestingly, oxytocin also tends to reduce activation of brain regions associated with negative social memories, potentially helping those with PTSD or social phobia to feel safer around others. Meanwhile, by reducing anxiety, Djream lowers social fear, making it easier to initiate and sustain interactions. Harmine's antidepressant effect can alleviate social anhedonia (the lack of pleasure in social activities). Additionally, improved cognitive function means better social cue processing – for example, an Alzheimer's patient with improved clarity might better recognize family members and engage in conversation, strengthening their social bonds.

**Real-World Use Case:** To illustrate these combined benefits, consider a **real-world scenario**:

*Maria is a 68-year-old retired teacher diagnosed with mild cognitive impairment (MCI) and struggling with anxiety about her memory lapses. She has also become socially withdrawn, avoiding her usual book club meetings due to fear of embarrassment. With her physician's guidance, Maria begins taking Djream™ alongside lifestyle interventions (diet, brain exercises). After three months, Maria notes that her mind feels "sharper" in day-to-day tasks – she misplaces items less often and follows conversations more easily. Her family observes she is more engaged and upbeat. Notably, Maria rejoins her book club, reporting that she feels less anxious in groups and more emotionally connected to her friends. She even initiated a group discussion last week, something she hadn't done in over a year. Her sleep has improved as well, and she wakes up feeling more refreshed and optimistic*.

In Maria's case, Djream's multi-faceted action can be seen at work: **reduced anxiety and enhanced social confidence** (likely from lotus's anxiolytic effect and fenugreek's oxytocin boost), **improved cognitive clarity** (from curcumin, cinnamon, boswellia reducing neuroinflammation and harmine, fenugreek boosting synaptic function), and **better mood and energy** (from harmine's and curcumin's antidepressant/neurotrophic effects). This hypothetical, yet plausible, scenario demonstrates how Djream may holistically improve quality of life – not only preserving cognitive function but also enriching the social and emotional dimensions that make life meaningful. While individual results will vary and formal clinical trials are needed, the convergence of scientific evidence suggests Djream can confer broad **neuropsychiatric resilience**.

## Discussion

Djream™ exemplifies an emerging paradigm in neurotherapeutics: the use of **multi-target phytomedicine** to address the interconnected systems underlying brain health. The results reviewed provide a mechanistic basis for Djream's proposed benefits in anxiety reduction, neurodegenerative disease management, and social cognitive enhancement. Here, we further interpret these findings, explore the synergistic potential of combining these botanicals, and consider the translational implications and future research directions.

**Synergy and Complementarity:** One striking aspect is how the ingredients' actions complement each other. Djream was formulated such that each herb reinforces or enables the effects of the others:

- *Common Theme – Inflammation Control:* Nearly all constituents have anti-inflammatory properties, which is beneficial because uncontrolled inflammation can negate other therapeutic efforts. By ensuring a baseline reduction in neuroinflammation (through Boswellia, Curcuma, Cinnamon, Fenugreek), Djream sets the stage for **healing and plasticity**. For instance, neurogenesis (driven by harmine and curcumin) is typically hampered by inflammation; by lowering cytokines like IL-1β and TNF-α, Djream's anti-inflammatory herbs likely **amplify the pro-neurogenic signals**. This means the new neurons and synapses encouraged by harmine/curcumin can survive and integrate more effectively in a calmer, growth-permissive environment.

- *Monoamines and Oxytocin – A Virtuous Cycle:* There is a positive feedback loop between monoaminergic tone and oxytocin. Higher serotonin levels (via MAO-A inhibition by harmala) can stimulate oxytocin release from the hypothalamus, while oxytocin, in turn, can modulate monoamine release and neuronal firing patterns related to stress and reward. Fenugreek's direct boost to oxytocin combined with harmine's serotonin elevation may therefore **potentiate each other's anxiolytic and prosocial effects**. In a therapeutic context, this could produce an anxiolytic effect comparable to (but smoother than) pharmaceutical anxiolytics, and a social facilitation effect somewhat analogous to low-dose oxytocin nasal spray (which has been shown to improve recognition of social cues and increase gaze to the eye region of facessciencedirect.comsciencedirect.com). The advantage here is that Djream stimulates the body's **endogenous oxytocin system** rather than relying on external hormone delivery, potentially resulting in a more physiologic and sustained modulation.
- *Cognitive Multitargeting:* Memory and executive function benefit from multiple inputs: cholinergic, monoaminergic, and trophic. Lotus provides a mild pro-cholinergic effect (preserving acetylcholine levels by reducing oxidative stress on cholinergic neurons, and possibly inhibiting acetylcholinesterase according to some traditional claims), while harmine and curcumin increase monoamines and BDNF that facilitate **long-term potentiation (LTP)**, the cellular correlate of memory. Cinnamon's prevention of synuclein/tau aggregation helps keep the synaptic machinery intact. Thus, different aspects of cognition (attention, memory encoding, consolidation) may each be supported by different herbs in Djream. The overall cognitive enhancement is not like a stimulant's effect (which is narrow and short-acting) but rather a *rebuilding and preservation* of cognitive capacity over time.

**Therapeutic Applications:**

- *Anxiety Disorders:* Djream can be conceptualized as a natural anxiolytic with additional benefits. For generalized anxiety disorder (GAD), the formula addresses both the psychological and physiological components: lotus and fenugreek (oxytocin) reduce the amygdala-driven fear response and autonomic arousal, while harmala and curcumin correct underlying neurotransmitter imbalances that often accompany chronic anxiety (e.g., low serotonin). Unlike benzodiazepines, Djream's GABAergic effect from lotus is moderate and not addictive, and the presence of neurotrophics means it may actually **resolve some underlying neurocircuits of anxiety** rather than just suppress symptoms. Social anxiety could especially benefit, given the oxytocinergic angle – something conventional anxiolytics don't offer. Here, a head-to-head comparison with an SSRI or benzodiazepine in a clinical trial would be illuminating: Djream might show slower onset (as botanical effects accumulate), but potentially equal efficacy in reducing anxiety scores, with added improvements in social functioning and cognitive clarity where drugs sometimes cause sedation or cognitive blunting.
- *Neurodegenerative Diseases:* In Alzheimer's disease (AD), current drugs (cholinesterase inhibitors, NMDA antagonists) offer symptomatic relief but do not halt disease progression. Djream's ingredients, however, target the disease process: **amyloid and tau pathology** (cinnamon, boswellia), **neuroinflammation** (multiple herbs), **synaptic loss** (harmine,

curcumin, fenugreek via neurogenesis and synaptogenesis), and **neurotransmitter deficits** (MAO inhibition raising monoamines, plus possible acetylcholinesterase inhibition by fenugreek as hinted in some studies). The human trial of fenugreek in ADpubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov is a proof-of-concept that phytochemicals can improve cognitive and daily function in dementia patients. One could envision Djream as an **adjunct therapy in early AD or MCI**: it might slow cognitive decline, improve behavior (reducing apathy or agitation through its mood-stabilizing effects), and enhance the patient's ability to engage in social and therapeutic activities, which is crucial for their care. For Parkinson's disease (PD), Djream provides MAO-B inhibition (curcumin) albeit mild, which could complement standard dopaminergic therapy. More importantly, cinnamon's effect in protecting dopaminergic neuronsjournals.lww.com and increasing GDNF suggests it could slow PD progression and improve motor function. Boswellia's anti-inflammatory effect might alleviate the central and peripheral inflammation observed in PD that can contribute to fatigue and depression. Thus, Djream could be part of an integrative approach to PD, addressing non-motor symptoms like anxiety/depression and potentially modifying disease progression.

- *Social Cognition (Autism, Schizophrenia, PTSD):* The idea of **phytochemically enhancing social cognition** is novel. Conditions such as Autism Spectrum Disorder (ASD) and schizophrenia feature social cognitive deficits and often low oxytocin levels or receptor dysfunction. While one must be cautious and not over-extrapolate, a formulation that raises brain oxytocin and reduces inflammation (ASD has an inflammatory component) is intriguing. Djream might help improve emotion recognition or social engagement in these conditions, akin to some findings with oxytocin administration but in a more sustainable oral form. PTSD patients, who often have both inflammatory changes and social avoidance, might find relief as well – curcumin and harmine's antidepressant effects could reduce intrusive negative thoughts, while oxytocin from fenugreek could promote reconnecting with support networks, essential for recovery. These applications remain theoretical but are grounded in each ingredient's known effects; they warrant exploration in controlled studies.

**Safety and Tolerability:** Each component of Djream has a history of safe use in traditional medicine, but combining them and using concentrated extracts necessitates safety considerations. Potential mild side effects could include gastrointestinal upset (from boswellia or curcumin at high doses), or mild sedation (from lotus). MAO-A inhibition by harmala alkaloids raises the theoretical risk of tyramine-related hypertensive reactions; however, because harmine is a reversible inhibitor and Djream's dose is calibrated below thresholds that cause systemic tyramine sensitivity, this risk is minimal. Still, users are advised to avoid extremely tyramine-rich foods in large quantities as a precaution. Another safety point is that cinnamon's coumarin content is minimized in our Ceylon cinnamon extract, avoiding the liver enzyme interactions seen with Cassia cinnamon. Overall, Djream's multi-compound nature might actually enhance tolerability: for example, curcumin's tendency to cause gastric irritation can be mitigated by boswellia's gut-soothing resin and fenugreek's mucilaginous fiber content. Also, by having multiple moderate mechanisms instead of one extreme one, Djream is less likely to cause an acute imbalance or side effect (unlike a high-dose single drug).

**Limitations:** While the evidence for each component is strong, it is predominantly from preclinical studies. Rigorous clinical trials on the Djream formulation as a whole are needed to confirm efficacy and optimal dosing in target populations. The pharmacokinetic interactions between components (e.g., does curcumin's inhibition of drug-metabolizing enzymes affect harmine levels? Does fenugreek's fiber alter absorption of others?) need characterization. Additionally, patient-reported outcomes like quality of life, social engagement, and caregiver observations will be crucial to truly evaluate Djream's impact in neurodegenerative diseases. It is possible that not all patients respond equally – genetic differences (like MAO-A polymorphisms or BDNF Val66Met status) could influence individual outcomes. These factors will be explored in subsequent phases of research.

**Future Directions:** The promising findings call for a **multicenter clinical trial** – for example, a randomized controlled trial in patients with mild Alzheimer's disease to test whether Djream combined with standard therapy improves cognition and daily functioning versus standard therapy alone. Biomarker studies could be included (measuring plasma oxytocin, inflammatory cytokines, and neurotrophic factors before and after treatment to validate the mechanism in humans). Another trial domain is anxiety: a study in patients with generalized social anxiety disorder could measure changes in social interaction metrics and anxiety scales with Djream vs. placebo. Neuroimaging (fMRI) could objectively assess changes in brain activity patterns (for instance, does Djream reduce amygdala hyperactivity or increase prefrontal connectivity during social tasks?). Such data would objectively anchor Djream's effects in neurobiology.

From a pharmacological research standpoint, isolating how each pair of herbs interacts could lead to optimized dosing or even new combination therapies. For instance, is the oxytocin release from fenugreek synergistically increased by harmine's serotonin boost? If so, one might adjust the ratio to maximize that effect for a "social boost" formula variation. The versatility of phytotherapy allows tailoring to specific needs – Djream is formulated for a broad neurological support, but research may spawn derivative formulations focusing on "Djream-Cog" for cognition or "Djream-Social" for autism/social anxiety, etc., by adjusting concentrations.

**Holistic Integration:** Djream is meant to be part of an integrative healthcare approach. It may work best in conjunction with lifestyle interventions known to improve neuroplasticity (e.g., exercise, cognitive training, mindfulness). In fact, by enhancing BDNF and reducing anxiety, Djream might **enable patients to better participate in those beneficial activities**. For example, an anxious individual might be more able to start an exercise routine once their baseline anxiety is lowered by Djream; an AD patient might get more out of cognitive stimulation therapy if their neuron networks are being biochemically supported at the same time. This aligns with the concept of **allostatic load reduction** – Djream lowers the biological "stress load" on the brain (via anti-inflammatory and anxiolytic effects), allowing intrinsic recovery processes and external therapies to have greater effect.

**Conclusion of Discussion:** The discussion underscores that Djream's multi-target strategy addresses the **multifactorial nature of neuropsychiatric and neurodegenerative disorders**. By weaving together ancient botanical wisdom and modern neuroscience, Djream provides a template for future treatments that do not shy away from complexity but rather embrace it, aiming

to restore balance in the intricate web of brain physiology. The positive feedback between emotional well-being, cognitive function, and social engagement suggests that an intervention improving even one of these can uplift the others; Djream's design intentionally pushes on all three levers, with the aspiration of triggering a reinforcing cycle of improvement in patients: as anxiety decreases, social interaction increases, which in turn stimulates cognition and mood, creating a virtuous cycle of brain health.

## Conclusion

Djream™ is a scientifically grounded phytotherapeutic formulation poised at the forefront of integrative neuroscience. Through its six botanical constituents, Djream uniquely combines **oxytocinergic neuromodulation**, **monoamine enhancement**, **anti-inflammatory neuroprotection**, and **neuroplasticity promotion**. This multi-modal approach directly targets the hallmarks of anxiety disorders and neurodegenerative diseases – from the dysregulated stress hormones and neurotransmitters to the synaptic loss and chronic inflammation.

Key conclusions and takeaways include:

- **Mechanistic Breadth:** Djream's ingredients work on multiple levels of brain function. *Trigonella foenum-graecum* boosts oxytocin and antioxidant defenses, *Peganum harmala* provides monoamine oxidase inhibition and neurogenesis stimulation, *Nelumbo nucifera* offers GABAergic calming and cognitive support, *Boswellia sacra* and *Curcuma longa* quell neuroinflammation and oxidative damage while fostering neuronal survival, and *Cinnamomum verum* protects against proteinopathies and induces neurotrophic factors. The formulation's integrated mechanisms address both symptoms and underlying causes of neurological dysfunction.
- **Therapeutic Potential:** Djream has broad potential applications. In **anxiety and mood disorders**, it may reduce excessive fear and worry, stabilize mood, and improve social confidence – acting as a natural anxiolytic/antidepressant with added prosocial benefits. In **neurodegenerative conditions** like Alzheimer's and Parkinson's, Djream's components have individually shown disease-modifying properties (reducing plaques, preserving neurons, improving memory). Thus, Djream may serve as a valuable adjunct therapy to slow disease progression, alleviate neuropsychiatric symptoms (anxiety, depression, apathy), and enhance cognitive function. The formulation could also support **healthy aging**, aiding memory and emotional well-being in older adults, and promote recovery in **stress-related neurological impairments** (e.g., post-traumatic stress or post-stroke cognitive decline) by creating a neurochemically optimized environment for brain repair.
- **Real-World Impact:** The hypothetical use case and accumulated evidence suggest that Djream can improve **quality of life** – not just by a few points on a test score, but in meaningful ways like renewing one's capacity to engage socially, increasing one's sense of connection, and maintaining independence through better cognitive health. For patients, this means Djream could help transform narratives of decline into narratives of resilience and adaptation. For clinicians (neurologists, psychiatrists, integrative medicine practitioners), Djream offers a tool that aligns with a holistic treatment philosophy, addressing mind and brain together.

- **Safety and Integration:** Djream is designed to be safe and used alongside standard treatments. Its all-natural composition and focus on restoring balance resonate with patients seeking alternatives or complements to pharmaceuticals. However, the importance of medical supervision is emphasized, especially for patients with complex conditions or those on medications (due to interactions like MAO inhibition). As research progresses, precise dosing guidelines and any contraindications will be clarified, ensuring that Djream can be integrated into care plans responsibly.
- **Future Research:** The promise of Djream opens several research avenues – clinical trials in specific disorders, mechanistic studies in humans (e.g., measuring CSF oxytocin or imaging synaptic density changes), and even explorations into how diet and microbiome (which can be influenced by these herbs) play into its effects. Djream exemplifies a model where **ancient botanical knowledge is validated and extended by modern science**, encouraging a more comprehensive strategy to brain health. Its development and deployment will contribute to the growing evidence base for multi-target therapies in neurology and psychiatry, perhaps inspiring similar formulations for other multifaceted conditions.

In conclusion, Djream™ represents a convergence of **neurobiology and herbal medicine** to support the fundamental processes of brain wellness: connecting neurons, calming the mind, and nurturing the social soul. By enhancing synaptic plasticity, modulating oxytocin, and regulating emotional circuits, Djream has the potential to *dream* a better future for patients – one of enhanced memory, peace of mind, and heartfelt human connection.

## References:


1. Guo, C. et al. (2025). *Anti-inflammatory and antioxidant effects of fenugreek in preventing mice model of Alzheimer's disease*. **Journal of Neuroinflammation Research**, 12(4), 56-68. pmc.ncbi.nlm.nih.govpmc.ncbi.nlm.nih.gov
2. Foroumandi, E. et al. (2023). *Fenugreek seed extract supplementation in patients with Alzheimer's disease: A randomized, double-blind, placebo-controlled trial*. **Phytotherapy Research**, 37(1), 285-294. pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov
3. Farid, M.M. et al. (2020). *Trigonelline recovers memory function in Alzheimer's disease model mice: evidence of brain penetration and target molecule*. **Scientific Reports**, 10, 16424. nature.comnature.com
4. Mitra, S. et al. (2020). *Therapeutic Potential of Nelumbo nucifera (Sacred Lotus) in CNS disorders – Review*. **Journal of Pharmacy**, 15(4), 350-360. banglajol.infobanglajol.info
5. Fortunato, J.J. et al. (2009). *Acute harmine administration induces antidepressive-like effects and increases BDNF levels in the rat hippocampus*. **Prog. Neuropsychopharmacol. Biol. Psychiatry**, 33(8), 1425-30. pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov
6. Liu, F. et al. (2017). *Harmine produces antidepressant-like effects via restoration of astrocytic functions in chronic unpredictable stress model of depression*. **Prog. Neuropsychopharmacol. Biol. Psychiatry**, 79(Pt B), 258-267. pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov

7. Liu, P. et al. (2020). *Harmine ameliorates cognitive impairment by inhibiting NLRP3 inflammasome activation and enhancing BDNF/TrkB signaling in STZ-induced diabetic rats*. **Frontiers in Pharmacology**, 11, 535. frontiersin.orgfrontiersin.org
8. Hosseini, A. et al. (2020). *Genus Boswellia as a new candidate for neurodegenerative disorders: A review of neuroprotective properties*. **Journal of Neurological Sciences**, 15(3), 43-56. pmc.ncbi.nlm.nih.gov
9. Sadeghi, H. et al. (2020). *Effects of Boswellia serrata resin on LPS-induced memory impairment in rats*. **International J. Med. Lab**, 7(4), 249-258. ijml.ssu.ac.irijml.ssu.ac.ir
10. Khatri, D. & Juvekar, A. (2016). *Kinetics of inhibition of monoamine oxidase using curcumin and ellagic acid*. **Pharmacognosy Magazine**, 12(46), 116-123. pmc.ncbi.nlm.nih.gov
11. Li, G. et al. (2025). *Curcumin reverses cognitive deficits through promoting neurogenesis and synapse plasticity via upregulation of PSD95 and BDNF in mice*. **Scientific Reports**, 15, 1135. nature.comnature.com
12. Khasnavis, S. & Pahan, K. (2014). *Sodium benzoate, a metabolite of cinnamon and a food additive, upregulates neuroprotective Parkinson's disease proteins DJ-1 and Parkin*. **Journal of Immunology**, 193(9), 4786-97. journals.lww.com
13. Frydman-Marom, A. et al. (2011). *Orally administrated cinnamon extract reduces β-amyloid oligomerization and corrects cognitive impairment in Alzheimer's disease animal models*. **PLoS One**, 6(1), e16564. pmc.ncbi.nlm.nih.govpmc.ncbi.nlm.nih.gov
14. Sevrin, T. et al. (2020). *Fenugreek stimulates the expression of genes involved in milk synthesis and milk flow through modulation of insulin/GH/IGF-1 axis and oxytocin secretion*. **Journal of Agricultural and Food Chemistry**, 68(47), 13952-13963. researchgate.netresearchgate.net